Skip to main content
. Author manuscript; available in PMC: 2020 Jun 30.
Published in final edited form as: Clin Cancer Res. 2018 Mar 7;24(11):2585–2593. doi: 10.1158/1078-0432.CCR-17-3811

Figure 2.

Figure 2.

Efficacy of SN38-TOA nanoparticles (NP) on BR6 flank xenografts. A, Tumor growth inhibition by SN38-TOA. Trk-B-expressing SH-SY5Y (BR6) cells were implanted subcutaneously in the flank of each mouse. All mice (n = 10/arm) were treated intravenously via tail vein injections twice per week for 4 weeks when tumors reached a volume of 0.2 cm3. SN38-TOA nanoparticles and CPT-11 were given at doses equivalent to 10 and 25 mg/kg drug, respectively. B, Event-free survival graph. Mice were removed from the study when the tumor volumes reached 3.0 cm3. SN38-TOA nanoparticles are more effective than CPT-11 (P < 0.0001) at inhibiting tumor growth and extending survivability.